Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc reports news on a hub-and-spoke biotherapeutics model built around internal programs and Founded Entities. Recurring updates cover portfolio strategy, annual and half-year results, capital allocation, and clinical development across medicines for inflammatory, immunological, oncologic, gastrointestinal, neurological and neuropsychiatric disorders.
Company news frequently includes deupirfenidone for idiopathic pulmonary fibrosis, LYT-200, a fully human anti-galectin-9 monoclonal antibody for myeloid malignancies, and Seaport Therapeutics programs using the Glyph platform for oral neuropsychiatric medicines. Other developments include scientific publications, clinical data releases, board and leadership changes, shareholder voting matters and capital-structure disclosures tied to PureTech and its Founded Entities.
PureTech (Nasdaq:PRTC) will showcase its deupirfenidone (LYT-100) program for idiopathic pulmonary fibrosis at the ATS International Conference 2026 in Orlando, May 15-20, 2026.
Sessions will cover the Phase 3 SURPASS-IPF head-to-head trial vs. pirfenidone and deep learning HRCT analyses from the Phase 2b ELEVATE IPF trial.
PureTech Health (PRTC) reported 2025 results and operational updates on April 29, 2026. Key facts: PureTech-level cash and short-term investments were $277.1M at Dec 31, 2025 and $248.1M at Mar 31, 2026; the company states an operational runway through the end of 2028.
Program highlights: Celea's deupirfenidone is Phase 3-ready with orphan designations and a near-complete external fundraising targeting close in early Q3 2026; Gallop and Seaport filed S-1 registration statements for potential IPOs.
PureTech (Nasdaq: PRTC, LSE: PRTC) intends to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading on the London Stock Exchange as its primary venue.
PureTech expects to file Form 25 around May 11, 2026, with Nasdaq ADSs' last trading day on or about May 20, 2026, and plans to pursue Form 15F to suspend and terminate SEC reporting within 90 days if no SEC objection.
Seaport Therapeutics appointed Dr. Sharon Mates to its Board of Directors on April 27, 2026. Dr. Mates co-founded and led Intra-Cellular Therapies through commercialization of CAPLYTA® and its 2025 acquisition by Johnson & Johnson for approximately $14.6 billion. CAPLYTA generated > $1.5 billion in sales prior to that acquisition. Dr. Mates currently serves on the boards of Medincell and Benitec (Nasdaq: BNTC) and will advise Seaport’s neuropsychiatry programs and governance.
PureTech (Nasdaq: PRTC) reported positive topline Phase 1b data for LYT-200 in relapsed/refractory high‑risk MDS and AML on April 22, 2026. Gallop Oncology selected an RP2D (12 mg/kg) and plans FDA discussion toward a potential registration trial in R/R HR‑MDS.
Key metrics: R/R HR‑MDS CR 27.3%, ORR 45.5%, conversion to transplant 18%; R/R AML composite CR 30.8%, ORR 42.3%, conversion to transplant 19.2%. Safety across N=101 showed no LYT‑200 related SAEs, discontinuations, or deaths.
PureTech Health (Nasdaq: PRTC) will publish its Annual Report and financial results for the year ended December 31, 2025 on Wednesday, April 29, 2026.
A presentation and conference call are scheduled for 9:00 AM EDT / 2:00 PM BST that day, with a live webcast available at https://investors.puretechhealth.com/events-presentations.
PureTech (Nasdaq: PRTC) announced publication of Phase 2b ELEVATE IPF results for deupirfenidone 825 mg TID in AJRCCM on April 2, 2026.
Key results: adjusted mean FVC difference +91 mL versus placebo at 26 weeks (p=0.02); HR for IPF progression 0.439 (p=0.0023); ~50% greater exposure versus pirfenidone 801 mg TID with similar overall AE rates.
Celea Therapeutics plans to initiate Phase 3 SURPASS-IPF in H1 2026 pending financing.
Seaport Therapeutics (PRTC Founded Entity) announced positive Phase 1 topline results for GlyphAgo on April 2, 2026.
GlyphAgo achieved a 6.8-fold bioavailability increase versus unmodified agomelatine, reduced PK variability by 10-fold, showed 9.6–14.5x dose-normalized AUC in SAD, was well tolerated in ~130 participants, and triggered plans for Phase 2a and Phase 2b trials.
PureTech (Nasdaq: PRTC) notes that its Founded Entity, Seaport Therapeutics, published first-in-human and preclinical data for GlyphAllo (SPT-300) in Science Translational Medicine on March 25, 2026.
The paper reports GlyphAllo as a triglyceride-mimetic prodrug that enabled oral allopregnanolone bioavailability, dose-dependent therapeutic plasma levels in humans, a significant cortisol reduction in a Phase 2a stress test (p=0.0001), and supported an ongoing global Phase 2b trial initiated July 2025.
PureTech (Nasdaq: PRTC) announced that CEO Robert Lyne and Co-founder/President Eric Elenko, PhD, will speak in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 at 11:20am EDT.
A live webcast will be available via the company's investor site at the scheduled time.